Fosamax (alendronate) is now approved for the treatment and prevention of osteoporosis caused by chronic glucocorticoids

Fosamax (alendronate) is now approved for the treatment and prevention of osteoporosis caused by chronic glucocorticoids.

This new indication is for men or women who take the equivalent of 7.5 mg/day or more of prednisone.

Patients on chronic steroids for rheumatoid arthritis, asthma, etc, are especially vulnerable to bone loss and fractures.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote